^
Association details:
| Biomarker: | BPIFB2 mutation |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | capecitabine (Thymidylate synthase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinical evaluation of germline polymorphisms (SNPs) associated with disease response to capecitabine in metastatic breast cancer (MBC) (TBCRC 015).
Published date:
05/16/2018
Excerpt:
...top GWAS signals included a novel SNP upstream of BP1FB2 (p = 0.0007, OR 27.6), an intronic variant SNP in ADAMTS3 (p = 0.0007, OR = 51.6), and an intronic variant in Wnt7a (p = 0.0009, OR 28.4) as associated with response to capecitabine treatment.
DOI:
10.1200/JCO.2018.36.15_suppl.1071
Trial ID:
